The vasculature and inflammatory bowel disease: Contribution to pathogenesis and clinical pathology

Inflammatory Bowel Diseases

Volumn 11, Issue 3, 2005, Pages 304-313

  Hatoum, Ossama A ^a   Binion, David G ^a  

^a FROEDTERT MEMORIAL LUTHERAN HOSPITAL   (United States)

Author keywords

Antiadhesion molecule therapy; Cell adhesion molecule; Crohn's disease; Endothelial; Hypercoagulability; Inflammatory bowel disease; Microvasculature; Ulcerative colitis; Vasculature; Vasculitis

Indexed keywords

ACETYLCHOLINE; ALICAFORSEN; ALPHA4 INTEGRIN ANTIBODY; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 8; BRADYKININ; CARDIOLIPIN ANTIBODY; CD40 ANTIGEN; CD40 LIGAND; CONTRAST MEDIUM; CORTICOSTEROID; CYCLOPHOSPHAMIDE; HEPARIN; HOMOCYSTEINE; INDOMETACIN; INTERCELLULAR ADHESION MOLECULE 1; LOW MOLECULAR WEIGHT HEPARIN; LUPUS ANTICOAGULANT; MESALAZINE; NATALIZUMAB; NITRIC OXIDE; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; PHOSPHOLIPID ANTIBODY; PROTEIN ANTIBODY; SHU 508; STEROID; STREPTOKINASE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERY LATE ACTIVATION ANTIGEN 4;

ANGIOGRAPHY; ARTERY DISEASE; ARTERY OCCLUSION; ATHEROSCLEROSIS; AUTOIMMUNE DISEASE; BLEEDING; BLEEDING TENDENCY; BLOOD CLOTTING DISORDER; BLOOD VESSEL INJURY; BONE DISEASE; CARDIOVASCULAR RISK; CELL INTERACTION; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CROHN DISEASE; DEEP VEIN THROMBOSIS; DISEASE COURSE; DOPPLER ECHOGRAPHY; DOPPLER FLOWMETRY; DRUG MECHANISM; DRUG TARGETING; ENDOTHELIUM CELL; ENTERITIS; GRANULOMATOSIS; HEART DISEASE; HEMOPHILIA; HUMAN; HYPERCOAGULABILITY; INTESTINE BLOOD FLOW; INTESTINE PERFUSION; LEUKOCYTE ADHERENCE; LEUKOCYTE MIGRATION; LUNG EMBOLISM; MICROANGIOPATHY; MICROVASCULATURE; MYOCARDITIS; NONHUMAN; PATHOGENESIS; PATHOLOGICAL ANATOMY; PERICARDITIS; PRIORITY JOURNAL; REVIEW; THROMBOEMBOLISM; THROMBOSIS; ULCERATIVE COLITIS; VASCULAR DISEASE; VASCULITIS; VASODILATATION; VON WILLEBRAND DISEASE;

CHRONIC DISEASE; COLITIS, ULCERATIVE; CROHN DISEASE; ENDOTHELIUM; HUMANS; INFLAMMATION; LEUKOCYTES; MICROCIRCULATION;

EID: 15944369567     PISSN: 10780998     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.MIB.0000160772.78951.61     Document Type: Review

References (147)

1. Talbot RW, Heppell J, Dozois RR, et al. Vascular complications of inflammatory bowel disease. Mayo Clin Proc. 1986;61:140-145.
2. Schapira M, Henrion J, Ravoet C, et al. Thromboembolism in inflammatory bowel disease. Acta Gastroenterol Belg. 1999;62:182-186.
3. Suarez Crespo JF, Nogueras LF, Teresa Galvan FJ, et al. [Thromboembolic complications in inflammatory bowel disease.] Gastroenterol Hepatol. 1997;20:180-183.
4. Hatoum OA, Spinelli KS, Abu-Hajir M, et al. Telford, GL., and Binion DG. Mesenteric Venous Thrombosis in Inflammatory Bowel Disease. J Clin Gastroenterol. 2004;(In Press)
5. Nuutinen H, Reunanen M, Farkkila M, et al. Association of Crohn's disease and ischemic heart disease. Gastroenterology. 1996;110A:981.
6. Nuutinen H, Reunanen M, Farkkila M, et al. Association of ulcerative colitis and ischemic heart disease. Gastroenterology. 1995;108A:886.
7. Lee JS, Duncan KM. Lymphatic and venous transport of water from rat jejunum: a vascular perfusion study. Gastroenterology. 1968;54:559-567.
8. Lam A, Borda IT, Inwood MJ, et al. Coagulation studies in ulcerative colitis and Crohn's disease. Gastroenterology. 1975;68:245-251.
9. Lake AM, Stauffer JQ, Stuart MJ. Hemostatic alterations in inflammatory bowel disease: response to therapy. Am J Dig Dis. 1978;23:897-902.
10. Souto JC, Martinez E, Roca M, et al. Prothrombotic state and signs of endothelial lesion in plasma of patients with inflammatory bowel disease. Dig Dis Sci. 1995;40:1883-1889.
11. Heneghan MA, Cleary B, Murray M, et al. Activated protein C resistance, thrombophilia, and inflammatory bowel disease. Dig Dis Sci. 1998;43:1356-1361.
12. Chamouard P, Grunebaum L, Wiesel ML, et al. Prothrombin fragment 1 + 2 and thrombin-antithrombin III complex as markers of activation of blood coagulation in inflammatory bowel diseases. Eur J Gastroenterol Hepatol. 1995;7:1183-1188.
13. Jorens PG, Hermans CR, Haber I, et al. Acquired protein C and S deficiency, inflammatory bowel disease and cerebral arterial thrombosis. Blut. 1990;61:307-310.
14. Aadland E, Odegaard OR, Roseth A, et al. Free protein S deficiency in patients with Crohn's disease. Scand J Gastroenterol. 1994;29:333-335.
15. Aadland E, Odegaard OR, Roseth A, et al. Free protein S deficiency in patients with chronic inflammatory bowel disease. Scand J Gastroenterol. 1992;27:957-960.
16. Kermode AG, Ives FJ, Taylor B, et al. Progressive dural venous sinus thrombosis treated with local streptokinase infusion. J Neurol Neurosurg Psychiatry. 1995;58:107-108.
17. Markowitz RL, Merit LR, Gryboski JD. Cerebral thromboembolic disease in pediatric and adult inflammatory bowel disease: case report and review of the literature. J Pediatr Gastroenterol Nutr. 1989;8:413-420.
18. Vecchi M, Cattaneo M, de Franchis R, et al. Risk of thromboembolic complications in patients with inflammatory bowel disease. Study of hemostasis measurements. Int J Clin Lab Res. 1991;21:165-170.
19. Dalekos GN, Manoussakis MN, Goussia AC, et al. Soluble interleukin-2 receptors, antineutrophil cytoplasmic antibodies, and other autoantibodies in patients with ulcerative colitis. Gut. 1993;34:658-664.
20. Chamouard P. Grunebaum L, Wiesel ML, et al. Prevalence and significance of anticardiolipin antibodies in Crohn's disease. Dig Dis Sci. 1994; 39:1501-1504.
21. Koutroubakis IE, Petinaki E, Anagnostopoulou E, et al. Anti-cardiolipin and anti-beta2-glycoprotein I antibodies in patients with inflammatory bowel disease, Dig Dis Sci. 1998;43:2507-2512.
22. Koutroubakis IE, Kritikos H, Mouzas IA, et al. Association between ulcerative colitis and systemic lupus erythematosus: report of two cases. Eur J Gastroenterol Hepatol. 1998;10:437-439.
23. Aichbichler BW, Petritsch W, Reicht GA, et al. Anti-cardiolipin antibodies in patients with inflammatory bowel disease. Dig Dis Sci. 1999; 44:852-856.
24. Bjerregaard LT, Nederby NJ, Fredholm L, et al. Hyperhomocysteinaemia, coagulation pathway activation and thrombophilia in patients with inflammatory bowel disease. Scand J Gastroenterol. 2002;37:62-67.
25. Maire F, Beaugerie L, Cohen M, et al. Factors associated with hyperhomocystinemia in Crohn's disease. Gastroenterol Clin Biol. 2001;25: 745-748.
26. Papa A, De SV, Danese S, et al. Hyperhomocystinemia and prevalence of polymorphisms of homocysteine metabolism-related enzymes in patients with inflammatory bowel disease. Am J Gastroenterol. 2001;96: 2677-2682.
27. Romagnuolo J, Fedorak RN, Dias VC, et al. Hyperhomocystinemia and inflammatory bowel disease: prevalence and predictors in a crosssectional study. Am J Gastroenterol. 2001;96:2143-2149.
28. Koutroubakis IE, Dilaveraki E, Vlachonikolis IG, et al. Hyperhomocysteinemia in Greek patients with inflammatory bowel disease. Dig Dis Sci. 2000;45:2347-2351.
29. Chowers Y, Sela BA, Holland R, et al. Increased levels of homocysteine in patients with Crohn's disease are related to folate levels. Am J Gastroenterol. 2000;95:3498-3502.
30. Vasilopoulos S, Saiean K, Emmons J, et al. Terminal ileum resection is associated with higher plasma homocysteine levels in Crohn's disease. J Clin Gastroenterol. 2001;33:132-136.
31. Thompson NP, Wakefield AJ, Pounder RE. Inherited disorders of coagulation appear to protect against inflammatory bowel disease. Gastroenterology. 1995;108:1011-1015.
32. Choi HK, Hernan MA, Seeger JD, et al. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet. 2002; 359:1173-1177.
33. Shine B, Berghouse L, Jones JE, et al. C-reactive protein as an aid in the differentiation of functional and inflammatory bowel disorders. Clin Chim Acta. 1985;148:105-109.
34. Deodhar SD. C-reactive protein: the best laboratory indicator available for monitoring disease activity. Cleve Clin J Med. 1989;56:126-130.
35. Fogelman AM, Seager J, Groopman JE, et al. Lymphokines secreted by an established lymphocyte line modulate receptor-mediated endocytosis in macrophages derived from human monocytes. J Immunol. 1983;131: 2368-2373.
36. Fogelman AM, Shechter I, Seager J, et al. Malondialdehyde alteration of low density lipoproteins leads to cholesteryl ester accumulation in human monocyte-macrophages. Proc Natl Acad Sci USA. 1980;77:2214-2218.
37. Binion DG, West GA, Ina K, et al. Enhanced leukocyte binding by intestinal microvascular endothelial cells in inflammatory bowel disease. Gastroenterology. 1997;112:1895-1907.
38. Urbich C, Dernbach E, Aicher A, et al. CD40 ligand inhibits endothelial cell migration by increasing production of endothelial reactive oxygen species. Circulation. 2002;106:981-986.
39. Andre P, Nannizzi-Alaimo L, Prasad SK, et al. Platelet-derived CD40L: the switch-hitting player of cardiovascular disease. Circulation. 2002; 106:896-899.
40. Henn V, Slupsky JR, Grafe M, et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature. 1998;391: 591-594.
41. Danese S. De la MC, Sturm A et al. Platelets trigger a CD40-dependent inflammatory response in the microvasculature of inflammatory bowel disease patients. Gastroenterology. 2003;124:1249-1264.
42. Vogel JD, Majors A, Sturm A. Collagen synthesis by human intestinal fibroblast is medulated by T-cells through the CD40/CD40 ligand pathway. Gastroenterology. 2001;120A:719.
43. Fear JD, Hutton WN. Ulcerative colitis complicated by complete heart block. Br Med J (Clin Res Ed). 1985;291:143.
44. Ballinger A, Farthing MJ. Ulcerative colitis complicated by Wenckebach atrioventricular block. Gut. 1992;33:1427-1429.
45. Mukhopadhyay D, Nasr K, Grossman BJ, et al. Pericarditis associated with inflammatory bowel disease. JAMA. 1970;211:1540-1542.
46. Mowat NA, Bennett PN, Finlayson JK, et al. Myopericarditis complicating ulcerative colitis. Br Heart J. 1974;36:724-727.
47. Goodman MJ, Moir DJ, Holt JM, et al. Pericarditis associated with ulcerative colitis and Crohn's disease. Am J Dig Dis. 1976;21:98-102.
48. Becker SA, Wishnitzer R, Botwin S, et al. Myopericarditis associated with inflammatory bowel disease. J Clin Gastroenterol. 1981;3:267-270.
49. Manomohan V, Subbuswamy SG, Willoughby CP. Crohn's disease and pericarditis. Postgrad Med J. 1984;60:682-684.
50. Farley JD, Thomson AB, Dasgupta MK. Pericarditis and ulcerative colitis. J Clin Gastroenterol. 1986;8:567-568.
51. Gould L, Patel C, Betzu R, et al. Pericarditis and ulcerative colitis. Am Heart J. 1986;111:802-803.
52. Jenss H, Becker EW, Weber P. Pericardial effusion during treatment with 5-aminosalicylic acid in a patient with Crohn's disease. Am J Gastroenterol. 1990;85:332-333.
53. Molnar T, Hogye M, Nagy F, et al. Pericarditis associated with inflammatory bowel disease: case report. Am J Gastroenterol. 1999;94:1099-1100.
54. Kristensen KS, Hoegholm A, Bohr L, et al. Fatal myocarditis associated with mesalazine. Lancet. 1990;335:605.
55. Fernando VT, Cutfield RG. Ulcerative colitis with pericarditis and tamponade. N Z Med J. 1988;101:61-62.
56. Collins CE, Rampton DS. Review article: platelets in inflammatory bowel disease-pathogenetic role and therapeutic implications. Aliment Pharmacol Ther. 1997;11:237-247.
57. Levy PJ, Tabares AH, Olin JW. Lower extremity arterial occlusions in young patients with Crohn's colitis and premature atherosclerosis: report of six cases. Am J Gastroenterol. 1997;92:494-497.
58. Novotny DA, Rubin RJ, Slezak FA, et al. Arterial thromboembolic complications of inflammatory bowel disease. Report of three cases. Dis Colon Rectum. 1992;35:193-196.
59. Braverman D, Bogoch A. Arterial thrombosis in ulcerative colitis. Am J Dig Dis. 1978;23:1148-1150.
60. Gaffney PR, Doyle CT, Gaffney A, et al. Paradoxical response to heparin in 10 patients with ulcerative colitis. Am J Gastroenterol. 1995;90:220-223.
61. Koutroubakis IE. Role of thrombotic vascular risk factors in inflammatory bowel disease. Dig Dis. 2000;18:161-167.
62. Evans RC, Wong VS, Morris AI, et al. Treatment of corticosteroidresistant ulcerative colitis with heparin-a report of 16 cases. Aliment Pharmacol Ther. 1997;11:1037-1040.
63. Folwaczny C, Wiebecke B, Loeschke K. Unfractioned heparin in the therapy of patients with highly active inflammatory bowel disease. Am J Gastroenterol. 1999;94:1551-1555.
64. Torkvist L, Thorlacius H, Sjoqvist U, et al. Low molecular weight heparin as adjuvant therapy in active ulcerative colitis. Aliment Pharmacol Ther. 1999;13:1323-1328.
65. Panes J, Granger DN. Leukocyte-endothelial cell interactions: molecular mechanisms and implications in gastrointestinal disease. Gastroenterology. 1998;114:1066-1090.
66. Schneiderman JH, Sharpe JA, Sutton DM. Cerebral and retinal vascular complications of inflammatory bowel disease. Ann Neurol. 1979;5:331-337.
67. Hull R, Hirsh J, Jay R, et al. Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. N Engl J Med. 1982;307:1676-1681.
68. Hull R, Delmore T, Carter C, et al. Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis. N Engl J Med. 1982;306:189-194.
69. Prajapati DN, Newcomer JR, Emmons J, et al. Successful treatment of an acute flare of steroid-resistant Crohn's colitis during pregnancy with unfractionated heparin. Inflamm Bowel Dis. 2002;8:192-195.
70. Basler RS. Ulcerative colitis and the skin. Med Clin North Am. 1980;64: 941-954.
71. Nelson J, Barron MM, Riggs JE, et al. Cerebral vasculitis and ulcerative colitis. Neurology. 1986;36:719-721.
72. Bonvin ER, Dosso AA, Safran AB. Occlusion of the ophthalmic artery in Crohn disease. Klin Monatsbl Augenheilkd. 1994;204:450-452.
73. Ruby AJ, Jampol LM. Crohn's disease and retinal vascular disease. Am J Ophthalmol. 1990;110:349-353.
74. Sedwick LA, Klingele TG, Burde RM, et al. Optic neuritis in inflammatory bowel disease. J Clin Neuroophthalmol. 1984;4:3-6.
75. Yassur Y, Snir M, Melamed S, et al. Bilateral maculopathy simulating 'cherry-red spot' in a patient with Crohn's disease. Br J Ophthalmol. 1981;65:184-188.
76. Duker JS, Brown GC, Brooks L. Retinal vasculitis in Crohn's disease. Am J Ophthalmol. 1987;103:664-668.
77. Owyang C, Miller LJ, Lie JT, et al. Takayasu's arteritis in Crohn's disease. Gastroenterology. 1979;76:825-828.
78. Soloway M, Moir TW, Linton DS Jr. Takayasu's arteritis. Report of a case with unusual findings. Am J Cardiol. 1970;25:258-263.
79. Tsuchiya M, Okazaki I, Mizumo O, et al. Aortitis syndrome associated with ulcerative colitis. Vasc Surg. 1976;10:176-181.
80. Miwa Y, Nagasako K, Sasaki H, et al. Aortitis syndrome associated with ulcerative colitis: report of a case. Gastroenterol Jpn. 1979;14:492-495.
81. Ishikawa H, Kondo Y, Yusa Y, et al. An autopsy case of ulcerative colitis associated with Takayasu's disease with a review of 13 Japanese cases. Gastroenterol Jpn. 1993;28:110-117.
82. Oyanagi H, Ishihata R, Ishikawa H, et al. Ulcerative colitis associated with Takayasu's disease. Intern Med. 1994;33:127-129.
83. Sato R, Sato Y, Ishikawa H, et al. Takayasu's disease associated with ulcerative colitis. Intern Med. 1994;33:759-763.
84. Yassinger S, Adelman R, Cantor D, et al. Association of inflammatory bowel disease and large vascular lesions. Gastroenterology. 1976;71: 844-846.
85. Knutson H, Lunderquist A, Lunderquist A. Vascular changes in Crohn's disease. Am J Roentgenol Radium Ther Nucl Med. 1968;103:380-385.
86. Geller SA, Cohen A. Arterial inflammatory cell infiltration in Crohn's disease. Arch Pathol Lab Med. 1983;107:473-475.
87. Wakefield AJ, Sankey EA, Dhillon AP, et al. Granulomatous vasculitis in Crohn's disease. Gastroenterology. 1991;100:1279-1287.
88. Cotran RS. Robbins Pathologic Basis of Disease. 5th ed. Philadelphia: W.B. Saunders Company; 1994.
89. Homan WP, Tang CK, Thorbjarnarson B. Acute massive hemorrhage from intestinal Crohn disease. Report of seven cases and review of the literature. Arch Surg. 1976;111:901-905.
90. McGarrity TJ, Manasse JS, Koch KL, et al. Crohn's disease and massive lower gastrointestinal bleeding: angiographic appearance and two case reports. Am J Gastroenterol. 1987;82:1096-1099.
91. Mellor JA, Chandler GN, Chapman AH, et al. Massive gastrointestinal bleeding in Crohn's disease: successful control by intra-arterial vasopressin infusion. Gut. 1982;23:872-874.
92. Harvey JC, Rotstein L, Steinhardt M, et al. Massive lower gastrointestinal bleeding; an unusual complication of Crohn's disease. Can. J Surg. 1978;21:444-445.
93. Lunderquist A, Lunderquist A. Angiography in ulcerative colitis. Am J Roentgenol Radium Ther Nucl Med. 1967;99:18-23.
94. Lunderquist A, Knutsson H. Angiography in Crohn's disease of the small bowel and colon. Am J Roentgenol Radium Ther Nucl Med. 1967; 101:338-344.
95. Erikson U, Fagerberg S, Krause U, et al. Angiographic studies in Crohn's disease and ulcerative colitis. Am J Roentgenol Radium Ther Nucl Med. 1970;110:385-392.
96. Brahme F. Mesenteric angiography in regional enterocolitis. Radiology. 1966;87:1037-1042.
97. Hulten L, Lindhagen J, Lundgren O, et al. Regional intestinal blood flow in ulcerative colitis and Crohn's disease. Gastroenterology 1977;72: 388-396.
98. Hulten L, Jodal M, Lindhagen J, et al. Blood flow in the small intestine of cat and man as analyzed by an inert gas washout technique. Gastroenterology. 1976;70:45-51.
99. Hulten L, Jodal M, Lindhagen J, et al. Colonic blood flow in cat and man as analyzed by an inert gas washout technique. Gastroenterology. 1976; 70:36-44.
100. Granger DN, Richardson PD, Kvietys PR, et al. Intestinal blood flow. Gastroenterology. 1980;78:837-863.
101. Bacaner MB. Quantitative measurement of regional colon blood flow in the normal and pathological human bowel. Gastroenterology. 1966;51: 764-777.
102. Angerson WJ, Allison MC, Baxter JN, et al. Neoterminal ileal blood flow after ileocolonic resection for Crohn's disease. Gut. 1993;34:1531-1534.
103. Guslandi M, Polli D, Sorghi M, et al. Rectal blood flow in ulcerative colitis. Am J Gastroenterol. 1995;90:579-580.
104. Leung FW, Su KC, Yonei Y, et al. Regional differences in mucosal hemodynamics in experimental colonic injury in rats. Dig Dis Sci. 1993; 38:1220-1223.
105. Goldberg BB, Liu JB, Burns PN, et al. Galactose-based intravenous sonographic contrast agent: experimental studies. J Ultrasound Med. 1993;12:463-470.
106. Di Sabatino A, Fulle I, Ciccocioppo R, et al. Doppler enhancement after intravenous levovist injection in Crohn's disease. Inflamm Bowel Dis. 2002;8:251-257.
107. Sheehan AL, Warren BF, Gear MW, et al. Fat-wrapping in Crohn' s disease: pathological basis and relevance to surgical practice. Br J Surg. 1992;79:955-958.
108. Weakley FL, Turnbull RB. Recognition of regional ileitis in the operating room. Dis Colon Rectum. 1971;14:17-23.
109. Fazio VW and Jones IT. Standard surgical treatment of Crohn's disease of small intestine and ileocolitis. In: Lee ECG, Nolan DJ, eds. Surgery of inflammatory Bowl Disease. Edinburgh: Churchill Livingstone; 1987.
110. Crohn BB, Ginsberg L, Oppenheimer GD. Regional ilietis: a clinical and pathological entity. JAMA. 1932;99:1323-1329.
111. Tateishi S, Arima S, Futami K. Assessment of blood flow in the small intestine by laser Doppler flowmetry: comparison of healthy small intestine and small intestine in Crohn's disease. J Gastroenterol. 1997;32: 457-463.
112. Hatoum OA, Binion DG, Otterson MF, et al. Acquired microvascular dysfunction in inflammatory bowel disease: Loss of nitric oxide-mediated vasodilation. Gastroenterology. 2003;125:58-69.
113. Funayama Y, Sasaki I, Naito H, et al. Remodeling of vascular wall in Crohn's disease. Dig Dis Sci. 1999;44:2319-2323.
114. Gibbons GH, Dzau VJ. The emerging concept of vascular remodeling. N Engl J Med. 1994;330:1431-1438.
115. Wakefield AJ, Pittilo RM, Sim R, et al. Evidence of persistent measles virus infection in Crohn's disease. J Med Virol. 1993;39:345-353.
116. Van Kruiningen HJ, Chiodini RJ, Thayer WR, et al. Experimental disease in infant goats induced by a Mycobacterium isolated from a patient with Crohn's disease. A preliminary report. Dig Dis Sci. 1986;31:1351-1360.
117. Wakefield AJ, Sawyerr AM, Dhillon AP, et al. Pathogenesis of Crohn's disease: multifocal gastrointestinal infarction. Lancet. 1989;2:1057-1062.
118. Davis RL, Bohlke K. Measles vaccination and inflammatory bowel disease: controversy laid to rest? Drug Saf. 2001; 24:939-946.
119. Nielsen SE, Nielsen OH, Vainer B, et al. [Inflammatory bowel disease - do microorganisms play a role?]. Ugeskr Laeger. 2002;164:5947-5590.
120. Elliman DA, Bedford HE. Measles, mumps and rubella vaccine, autism and inflammatory bowel disease: advising concerned parents. Paediatr Drugs. 2002;4:631-635.
121. Miller E. MMR vaccine: review of benefits and risks. J Infect. 2002;44: 1-6.
122. Dvorak AM, Monahan RA, Osage JE, et al. Crohn's disease: transmission electron microscopic studies. II. Immunologic inflammatory response. Alterations of mast cells, basophils, eosinophils, and the microvasculature. Hum Pathol. 1980;11:606-619.
123. Podolsky DK, Lobb R, King N, et al. Attenuation of colitis in the cottontop tamarin by anti-alpha 4 integrin monoclonal antibody. J Clin Invest. 1993;92:372-380.
124. Briskin M, Winsor-Hines D, Shyjan A, et al. Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue. Am J Pathol. 1997;151:97-110.
125. Salmi M, Granfors K, MacDermott R, et al. Aberrant binding of lamina propria lymphocytes to vascular endothelium in inflammatory bowel diseases. Gastroenterology. 1994;106:596-605.
126. Burgio VL, Fais S, Boirivant M, et al. Peripheral monocyte and naive T-cell recruitment and activation in Crohn's disease. Gastroenterology. 1995;109:1029-1038.
127. Binion DG, West GA, Volk EE, et al. Acquired increase in leucocyte binding by intestinal microvascular endothelium in inflammatory bowel disease. Lancet. 1998;352:1742-1746.
128. Kubes P, McCafferty DM. Nitric oxide and intestinal inflammation. Am J Med. 2000;109:150-158.
129. van Assche G, Rutgeerts P. Antiadhesion molecule therapy in inflammatory bowel disease. Inflamm Bowel Dis. 2002;8:291-300.
130. Dustin ML, Rothlein R, Bhan AK, et al. Induction by IL 1 and interferongamma: tissue distribution, biochemistry, and function of a natural adherence molecule (ICAM-1). J Immunol. 1986;137:245-254.
131. Rothlein R, Dustin ML, Martin SD, et al. A human intercellular adhesion molecule (ICAM-1) distinct from LFA-1. J Immunol. 1986;137:1270-1274.
132. Marlin SD, Springer TA. Purified intercellular adhesion molecule-1 (ICAM-1) is a ligand for lymphocyte function-associated antigen 1 (LFA-1). Cell. 1987;51:813-819.
133. Diamond MS. Staunton DE, de Fougerolles AR, et al. ICAM-1 (CD54): a counter-receptor for Mac-1 (CD11b/CD18). J Cell Biol. 1990;111: 3129-3139.
134. Kavanaugh AF, Davis LS, Nichols LA, et al. Treatment of refractory rheumatoid arthritis with a monoclonal antibody to intercellular adhesion molecule 1. Arthritis Rheum. 1994;37:992-999.
135. Bennett CF, Condon TP, Grimm S, et al. Inhibition of endothelial cell adhesion molecule expression with antisense oligonucleotides. J Immunol. 1994;152:3530-3540.
136. Nestle FO, Mitra RS, Bennett CF, et al. Cationic lipid is not required for uptake and selective inhibitory activity of ICAM-1 phosphorothioate antisense oligonucleotides in keratinocytes. J Invest Dermatol. 1994;103: 569-575.
137. Chiang MY, Chan H, Zounes MA, et al. Antisense oligonucleotides inhibit intercellular adhesion molecule 1 expression by two distinct mechanisms. J Biol Chem. 1991;266:18162-18171.
138. Hoke GD, Draper K, Freier SM, et al. Effects of phosphorothioate capping on antisense oligonucleotide stability, hybridization and antiviral efficacy versus herpes simplex virus infection. Nucleic Acids Res. 1991; 19:5743-5748.
139. Wickstrom E, Oligodeoxynucleotide stability in subcellular extracts and culture media, J Biochem Biophys Methods. 1986;13:97-102.
140. Yacyshyn BR, Bowen-Yacyshyn MB, Jewell L, et al. A placebocontrolled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease. Gastroenterology. 1998; 114:1133-1142.
141. Dignass A, Lynch-Devaney K, Kindon H, et al. Trefoil peptides promote epithelial migration through a transforming growth factor betaindependent pathway. J Clin Invest. 1994;94:376-383.
142. Ghosh S, Goldin E, Gordon FH, et al. Natalizumab for active Crohn's disease. N Engl J Med. 2003;348:24-32.
143. Fichera A, Cicchiello LA, Mendelson DS, et al. Superior mesenteric vein thrombosis after colectomy for inflammatory bowel disease: a not uncommon cause of postoperative acute abdominal pain. Dis Colon Rectum. 2003;46:643-648.
144. Hatoum OA, Miura H, Binion DG. The vascular contribution in the pathogenesis of inflammatory bowel disease. Am J Physiol Heart Circ Physiol. 2003;285:H1791-H1796.
145. Salmi M, Jalkanen S. Human leukocyte subpopulations from inflamed gut bind to joint vasculature using distinct sets of adhesion molecules. J Immunol. 2001;166:4650-4657.
146. Koizumi M, King N, Lobb R, et al. Expression of vascular adhesion molecules in inflammatory bowel disease. Gastroenterology. 1992;103: 840-847.
147. Binion DG, Rafiee P, Ramanujam KS, et al. Deficient iNOS in inflammatory bowel disease intestinal microvascular endothelial cells results in increased leukocyte adhesion. Free Radic Biol Med. 2000;29:881-888.